Evidence map›Paper›PMID 33802959›Full record

ArticleVaccines2021

Glyceraldehyde-3-phosphate Dehydrogenase Common Peptides of

David Salcines-Cuevas, Hector Terán-Navarro, Ricardo Calderón-Gonzalez, Paula Torres-Rodriguez, Raquel Tobes, Manuel Fresno, Jorge Calvo-Montes, I Concepción Pérez Del Molino-Bernal, Sonsoles Yañez-Diaz, Carmen Alvarez-Dominguez

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Autophagy · 2024
    Article
  4. TargetingVaccines · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

David Salcines-CuevasGrupo de Oncología y Nanovacunas, Instituto de Investigación Marqués de Valdecilla, 39011 Santander, Cantabria, Spain.ORCID 0000-0003-2627-0597
Hector Terán-NavarroGrupo de Oncología y Nanovacunas, Instituto de Investigación Marqués de Valdecilla, 39011 Santander, Cantabria, Spain.
Ricardo Calderón-GonzalezGrupo de Oncología y Nanovacunas, Instituto de Investigación Marqués de Valdecilla, 39011 Santander, Cantabria, Spain.ORCID 0000-0003-0841-3814
Paula Torres-RodriguezGrupo de Oncología y Nanovacunas, Instituto de Investigación Marqués de Valdecilla, 39011 Santander, Cantabria, Spain.
Raquel TobesAlamo Blanco, 18110 Granada, Andalucia, Spain.ORCID 0000-0001-7032-8720
Manuel FresnoCentro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid & DIOMUNE S.L., Parque Científico de Madrid, 28049 Madrid, Spain.
Jorge Calvo-MontesServicio de Microbiología, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Cantabria, Spain.
I Concepción Pérez Del Molino-BernalServicio de Microbiología, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Cantabria, Spain.
Sonsoles Yañez-DiazServicio de Dermatología, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Cantabria, Spain.
Carmen Alvarez-DominguezFacultad de Educación y Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja, Avda. La Paz 137, 26006 Logroño, La Rioja, Spain.
Instituto de Investigación Marqués de Valdecilla · ESMarqués de Valdecilla University Hospital · ESCentro de Biología Molecular Severo Ochoa · ESUniversidad Internacional De La Rioja · ES

Funding

Comisión Interministerial de Ciencia y Tecnología SAF2012-34203Comisión Interministerial de Ciencia y Tecnología SAF2016-75988-RComunidad de Madrid S2017/BMD-3671. INFLAMUNE-CMEuropean Cooperation in Science and Technology ENOVAInstituto de Investigación Marqués de Valdecilla INNVAL19/26Instituto de Salud Carlos III BIOIMIDInstituto de Salud Carlos III CIB16-NM009Instituto de Salud Carlos III DTS-00022Instituto de Salud Carlos III PI19-01580
6 · The paper itself

Abstract

Universal vaccines can be prepared with antigens common to different pathogens. In this regard, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a common virulence factor among pathogenic bacteria of the genera Listeria, Mycobacterium and Streptococcus. Their N-terminal 22 amino acid peptides, GAPDH-L1 (

Indexed as

adjuvantsglyceraldehyde-3-phosphate-dehydrogenaselisteriosispneumoniatuberculosisvaccines

Identifiers

PMID33802959
PMCPMC8002646
OpenAlexW3138367701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.